Media stories about Eiger Biopharmaceuticals (NASDAQ:EIGR) have been trending somewhat negative this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 49.7358765345838 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s rankings:
- Eiger Biopharmaceuticals (EIGR) Posts Quarterly Earnings Results, Hits Expectations (americanbankingnews.com)
- Oppenheimer Sticks to Its Buy Rating for Spero Therapeutics Inc (SPRO) (analystratings.com)
- Eiger BioPharmaceuticals, Inc. (streetinsider.com)
- Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results (finance.yahoo.com)
- Eiger BioPharma: 2Q Earnings Snapshot (finance.yahoo.com)
Eiger Biopharmaceuticals stock traded down $0.25 during trading on Friday, reaching $9.60. The company had a trading volume of 36,770 shares, compared to its average volume of 66,486. Eiger Biopharmaceuticals has a 52 week low of $7.46 and a 52 week high of $18.00. The stock has a market cap of $103.82 million, a P/E ratio of -1.98 and a beta of 1.68. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.51 and a current ratio of 4.51.
Several analysts recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $36.00 price target (down previously from $53.00) on shares of Eiger Biopharmaceuticals in a research note on Thursday, May 17th. Zacks Investment Research raised Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Tuesday, May 15th. Oppenheimer set a $26.00 price objective on Eiger Biopharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 11th. Piper Jaffray Companies upped their price objective on Eiger Biopharmaceuticals to $28.00 and gave the company an “overweight” rating in a research report on Friday, May 18th. Finally, ValuEngine raised Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 17th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Eiger Biopharmaceuticals currently has an average rating of “Buy” and an average price target of $28.63.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Featured Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.